C Suraci
Overview
Explore the profile of C Suraci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Giorda C, Mulas M, Manicardi V, Suraci C, Guida P, Marafetti L, et al.
Acta Diabetol
. 2012 Oct;
50(1):81-7.
PMID: 23053878
The time to achieve good metabolic control after diagnosis is essential for type 2 diabetes patients because it can influence long-term prognosis. This study aimed to elucidate the predictive role...
2.
Pitocco D, DiStasio E, Crino A, Manfrini S, Guglielmi C, Visalli N, et al.
Horm Metab Res
. 2007 Dec;
40(1):66-8.
PMID: 18085501
No abstract available.
3.
Picardi A, Visalli N, Lauria A, Suraci C, Buzzetti R, Merola M, et al.
Horm Metab Res
. 2006 Nov;
38(10):668-72.
PMID: 17075776
Background: In recent onset of type 1 diabetes, the residual beta cell function, assessed by baseline and/or stimulated C-peptide secretion, can be a useful parameter to establish the extension of...
4.
Pitocco D, Crino A, Di Stasio E, Manfrini S, Guglielmi C, Spera S, et al.
Diabet Med
. 2006 Aug;
23(8):920-3.
PMID: 16911633
Background: A number of recent studies underline the importance of vitamin D in the pathogenesis of Type 1 diabetes (T1D). Aims: The aim of this study was to investigate whether...
5.
Napoli A, Colatrella A, Botta R, Di Cianni G, Fresa R, Gamba S, et al.
Diabetes Res Clin Pract
. 2005 Feb;
67(3):267-72.
PMID: 15713360
Results: Of these women, 30.4% used hormonal contraceptives, 12.0% intra-uterine device (IUD), 10.7% declared they used no contraception, 47.0% only utilised barrier and/or natural methods. However, irrespective of their previous...
6.
Crino A, Schiaffini R, Manfrini S, Mesturino C, Visalli N, Beretta Anguissola G, et al.
Eur J Endocrinol
. 2004 May;
150(5):719-24.
PMID: 15132730
Objective: Various adjuvant therapies have been introduced along with intensive insulin therapy in patients with recent onset type 1 diabetes. Nicotinamide (NA), administered at diagnosis of the disease, can have...
7.
Pozzilli P, Pitocco D, Visalli N, Cavallo M, Buzzetti R, Crino A, et al.
Diabetologia
. 2000 Sep;
43(8):1000-4.
PMID: 10990077
Aims/hypothesis: Induction of tolerance to insulin is achievable in animal models of Type I (insulin-dependent) Diabetes mellitus by oral treatment with this hormone, which can lead to prevention of the...
8.
Cogoi S, Suraci C, Del Terra E, Diviacco S, van der Marel G, van Boom J, et al.
Antisense Nucleic Acid Drug Dev
. 2000 Sep;
10(4):283-95.
PMID: 10984122
Exogenous triplex-forming oligodeoxynucleotides (TFO) have the capacity to modulate in vivo the expression of individual genes. As the administration of TFO to cells is not without problems, we analyzed the...
9.
Parlapiano C, Marangi M, Campana E, Giovanniello T, Pantone P, Suraci C, et al.
Exp Clin Endocrinol Diabetes
. 1999 Sep;
107(5):328-9.
PMID: 10482047
Both anti neutrophil cell antibodies and anti endothelial cell antibodies were found in 7 out of 30 newly-diagnosed type-1 diabetic patients. This confirms the abnormal activation of the immunological system...
10.
Visalli N, Cavallo M, Signore A, Baroni M, Buzzetti R, Fioriti E, et al.
Diabetes Metab Res Rev
. 1999 Aug;
15(3):181-5.
PMID: 10441040
Background: Intensive insulin therapy is the gold standard by which Type 1 diabetes is treated. In addition to this therapy, administration of nicotinamide (NA) can be beneficial. This concept is...